about
Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, IndiaIs one sputum specimen as good as two during follow-up cultures for monitoring multi drug resistant tuberculosis patients in India?Comparative evaluation of GenoType MTBDRplus line probe assay with solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR-TB) at a tertiary care centre in IndiaEnhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TBCatching the missing million: experiences in enhancing TB & DR-TB detection by providing upfront Xpert MTB/RIF testing for people living with HIV in IndiaAlarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, IndiaThe Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant TuberculosisUse of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in IndiaPatient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: A Qualitative Study from a Drug Resistant TB Centre in IndiaFactors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective AnalysisImpact of introducing the line probe assay on time to treatment initiation of MDR-TB in Delhi, India.Source of previous treatment for re-treatment TB cases registered under the National TB control Programme, India, 2010.How did the TB patients reach DOTS services in Delhi? A study of patient treatment seeking behavior.LED-fluorescence microscopy for diagnosis of pulmonary tuberculosis under programmatic conditions in IndiaPiloting Upfront Xpert MTB/RIF Testing on Various Specimens under Programmatic Conditions for Diagnosis of TB & DR-TB in Paediatric Population.Addressing poverty through disease control programmes: examples from Tuberculosis control in IndiaGenotypic, Phenotypic and Clinical Validation of GeneXpert in Extra-Pulmonary and Pulmonary Tuberculosis in India.Direct Observation of Treatment Provided by a Family Member as Compared to Non-Family Member among Children with New Tuberculosis: A Pragmatic, Non-Inferiority, Cluster-Randomized Trial in Gujarat, India.Promoting tobacco cessation by integrating 'brief advice' in tuberculosis control programme.Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis.Meso level multi-disciplinary approach for reduction of pre-treatment loss to follow-up in Revised National Tuberculosis Control Program, Delhi, India.Innovatively addressing the challenge of maintaining binocular microscopes under Tuberculosis Programme in India - Is this feasible?Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.Use of Computer-Assisted Personal Interviewing and Information Management System in a Survey among HIV High-Risk Groups in India: Strengths, Weaknesses, Opportunities, and Threats Analysis.Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in IndiaCertification of TB culture and drug susceptibility testing laboratories through the Revised National Tuberculosis Control Programme (RNTCP)
P50
Q28477754-1E279778-93A5-403E-A8FD-57B75305D6BCQ28484087-91812BE0-AD65-424A-A7B7-D1DA44B26800Q28536857-FC281CA7-F324-481F-A774-2F0BEBEFDFD5Q28542451-514C87A1-42C2-4F7E-B60A-09857D2DCC63Q28543236-3FA05563-73B4-4412-9583-AA5D1CFB2B65Q28543967-F7F4F545-CB07-4446-9DED-0552E68F36F1Q28546035-419534BB-322D-4EDA-942A-095FCE35A17FQ28547389-89A2BA44-A709-4EB9-8186-496D3F54EAE6Q28547430-1BE40B67-216E-40C4-A633-D2AEDFB7CD9DQ28550398-11376DD1-FCD7-41D5-857E-C92CD4DB9B5EQ33945862-E29EDD94-61BF-42B1-8499-19A4AD37CA8CQ33981462-D855E9E3-B36D-4094-923C-C1427F6FFA00Q34374151-19109D09-11CB-4EEB-B8C3-55CC910665FFQ35018320-EA2320AC-D6A3-4819-918D-90FE73C9E6C8Q35808687-7F5DA45F-3DD9-4E5F-893A-33DF586289D9Q35883365-360B3BB4-C17C-43BC-BBDE-336E062615FFQ35928273-64D4C89F-2922-441C-9D02-9DBC30BB2366Q36552054-439DACF3-8F4B-44B6-B867-EE17A0BC79C9Q38726321-C481F4C7-336E-4194-9493-EE194F6D4203Q41572739-F54586D9-6F16-4D78-A2DA-0597674ED525Q47681629-C848CCBF-F1B6-4A34-A48B-FE39006C7240Q50848590-01370D3C-4114-4ADA-9707-F19B8FB32C4AQ52594133-BCA852D9-81E6-4ADD-831C-58ACE025D6BAQ55403708-3A33879F-2860-433D-9C81-7EE872F83185Q58580044-201197F5-D77B-4FDB-BEEC-0EF63A749D2DQ86453525-D38B486F-E5DF-4432-BD87-7A18A8A63979
P50
name
Kuldeep Singh Sachdeva
@en
type
label
Kuldeep Singh Sachdeva
@en
prefLabel
Kuldeep Singh Sachdeva
@en